Symbicort
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
AstraZeneca’s Symbicort ([budesonide + formoterol]) was the second inhaled corticosteroid/long-acting beta 2 agonist (ICS/LABA) drug combination to launch on the respiratory market, starting with approval for asthma. This was followed by approval for chronic obstructive pulmonary disease in the EU in 2003 and in the US in February 2009. In Japan, where Symbicort is co-promoted by Astellas and AstraZeneca, the drug received approval in August 2012. Budesonide is an ICS that exhibits potent glucocorticoid activity, and formoterol is a LABA that acts locally in the lungs as a bronchodilator.
TABLE OF CONTENTS
4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 Symbicort : Chronic obstructive pulmonary disease (COPD)
15 Symbicort : Asthma
LIST OF FIGURES
7 Figure 1: Symbicort for COPD – SWOT analysis
8 Figure 2: Datamonitor Healthcare’s drug assessment summary of Symbicort for COPD
9 Figure 3: Datamonitor Healthcare’s drug assessment summary of Symbicort for COPD
12 Figure 4: Symbicort sales for COPD across the US, Japan, and five major EU markets, by country, 2017–26
22 Figure 5: Symbicort for asthma – SWOT analysis
23 Figure 6: Datamonitor Healthcare’s drug assessment summary of Symbicort in asthma
24 Figure 7: Datamonitor Healthcare’s drug assessment summary of Symbicort in asthma
27 Figure 8: Symbicort sales for asthma across the US, Japan, and five major EU markets, by country, 2017–26
LIST OF TABLES
5 Table 1: Symbicort drug profile
6 Table 2: Overview of pivotal trial data for Symbicort in COPD
13 Table 3: Symbicort sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017–26
15 Table 4: Symbicort drug profile
17 Table 5: Symbicort pivotal trial data in asthma
20 Table 6: Symbicort late-phase trial data in asthma
28 Table 7: Symbicort sales for asthma in the US, Japan, and five major EU markets, by country ($m), 2017–26
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Advair 
Sign up to the